Nasdaq · CIK 0001048477 · PHARMACEUTICAL PREPARATIONS
BIOMARIN PHARMACEUTICAL INC
BMRN chart by TradingView
PRICE HISTORY
LIVE · NASDAQBMRN chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $3.2B
- EBITDA
- $0.5B
- FREE CASH FLOW
- $0.7B
- EPS
- $1.77
- GROSS MARGIN
- 77.73%
- ROIC
- 6.49%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
152.5x
+10%16.5x1305.6x
⤢
P / SALES (TTM)
3.3x
-78%3.3x14.9x
⤢
P / BOOK
1.8x
-70%1.7x6.9x
⤢
EV / EBITDA (TTM)
49.7x
+127%21.9x49.7x
⤢
EV / REVENUE (TTM)
4.2x
+28%3.2x4.2x
⤢
FCF YIELD (TTM)
6.63%
+9.8pp-3.18%8.00%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$1.0B
+254%⤢
EBITDA (DERIVED)
$0.2B
+$0.2B⤢
NET INCOME
$0.0B
+$0.1B⤢
EPS (DILUTED)
$0.23
+$0.45⤢
REVENUE GROWTH YOY
19.91%
-14.1pp-14.27%33.98%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
14.07%
+27.1pp-49.23%43.84%
⤢
RETURN ON CAPITAL
0.76%
-5.7pp0.76%6.49%
⤢
RETURN ON EQUITY (TTM)
1.15%
+19.0pp-22.78%21.02%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN79.51%
OPERATING MARGIN11.21%
NET MARGIN4.52%
FCF MARGIN14.07%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.1B
+$0.2B⤢
STOCK-BASED COMP
$0.1B
+128%⤢
CAPITAL EXPENDITURE
$0.0B
+10%⤢
SHARES OUTSTANDING
0.19B
+16%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.9B
+24%⤢
TOTAL DEBT
$4.2B
+601%⤢
DEBT / EBITDA (TTM)
14.4x
+1079%1.2x14.4x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 103.25%INSIDERS 0.34%OTHER / RETAIL 0.00%766 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 10.25% | 19.8M | $1.26B | +3.6% |
| Dodge & Cox Inc. | 7.53% | 14.6M | $929.2M | -0.1% |
| Primecap Management Company | 7.34% | 14.2M | $905.7M | -2.4% |
| Vanguard Capital Management LLC | 4.47% | 8.6M | $551.5M | NEW |
| Vanguard Portfolio Management LLC | 4.29% | 8.3M | $529.5M | NEW |
| AQR Capital Management, LLC | 3.97% | 7.7M | $489.8M | +14.8% |
| State Street Corporation | 3.77% | 7.3M | $465.5M | -3.0% |
| Viking Global Investors, L.P. | 3.65% | 7.1M | $450.6M | +17.0% |
| Citadel Advisors Llc | 2.33% | 4.5M | $288.0M | +230.7% |
| Geode Capital Management, LLC | 1.98% | 3.8M | $243.7M | +4.0% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.